

Perspective

Pulmonary Hypertension and its Complications

Isao Kubot^{*}

Department of Cardiology, Yamagata University School of Medicine, Yamagata, Japan

DESCRIPTION

Pulmonary hypertension is a type of hypertension that affects the arteries on the right side of the lungs and heart. In a form of pulmonary hypertension called Pulmonary Arterial Hypertension (PAH), blood vessels in the lungs are narrowed, blocked, or destroyed. The damage slows blood flow through the lungs and raises blood pressure in the pulmonary arteries. The heart must work harder to pump blood through the lungs. Unnecessary problems eventually weaken the heart muscle and make it dysfunctional. In a few people, pulmonary high blood pressure slowly receives worse and may be life- changing.

Although there may be no treatment for a few sorts of pulmonary high blood pressure, remedy can assist lessen signs and symptoms and ameliorate exceptional of life. The symptoms of pulmonary high blood pressure increase slowly. You won't word them for months or maybe years. Symptoms worsen because the grievance progresses. Pulmonary high blood pressure releases carbon dioxide and absorbs oxygen. Blood normally flows smoothly to the left side of the heart through the blood vessels of the lungs include pulmonary arteries, capillaries, vena cava. However, changes in the pulmonary artery can cause the arterial wall to become stiff, bloated, and thickened.

Pulmonary hypertension caused by other health conditions, Blood disorders including polycythemia Vera and essential thrombocythemia. An inflammatory disease similar to sarcoidosis and vasculitis. Metabolic diseases including glycogen storage disease. The Eisenmenger's pattern is a type of natural heart disease that causes pulmonary hypertension. Most commonly, it is caused by a large hole in the heart between the two lower chambers (ventricular) of the heart, called the interventricular septal curvature.

This hole in the heart causes blood to flow improperly into the heart. Oxygenated blood (red blood) mixes with deoxygenated blood (blue blood). Blood also returns to the lungs, rather than flowing to the rest of the body, increasing pressure in the pulmonary arteries and causing pulmonary hypertension. Pulmonary hypertension is more commonly diagnosed in people between the ages of 30 and 60. The risk of developing Group 1 pulmonary hypertension, called pulmonary arterial hypertension (PAH), can increase with age. However, PAH of unknown cause (idiopathic PAH) is more common in young adults.Implicit complications of pulmonary hypertension include dilation of the right heart and heart failure (pulmonary heart disease). In corpulmonale, the lower right chamber of the heart (ventricular) expands. To move blood through a narrowed or occluded pulmonary artery, it must be pumped stronger than normal. Having pulmonary high blood pressure will increase the hazard of blood clots with inside the small arteries .Irregular heartbeats (arrhythmias). Certain arrhythmias because of pulmonary high blood pressure may be life- threatening, bleeding withinside the lungs. Pulmonary high blood pressure can result in lifethreatening bleeding into the lungs and coughing up blood.

Heart has two upper chambers atria and two lower chambers ventricular. Each time blood flows through the heart, the lower right ventricle pumps blood to the lungs through a large blood vessel (pulmonary artery). In the lungs, blood releases carbon dioxide and absorbs oxygen. Blood usually tends to flow to the left side of the heart through the blood vessels of the lungs (pulmonary arteries, capillaries, veins). However, changes in the cells the pulmonary arteries can cause the walls of the arteries to become stiff, swollen, and thickened. These changes can slow or block blood flow through the lungs, causing pulmonary hypertension.

Citation: Kubot I (2022) Pulmonary Hypertension and its Complications. Cardiovasc Pharm. 11:274.

Correspondence to: Isao Kubot, Department of Cardiology, Yamagata University School of Medicine, Yamagata, Japan, E-mail: isaokubot45@gmail.com Received: 01-Mar-2022, Manuscript No. CPO-22-16362; Editor assigned: 04-Mar-2022, Pre QC No. CPO-22-16362(PQ); Reviewed: 18-Mar-2022, QC No. CPO-22-16362; Revised: 25-Mar-2022, Manuscript No. CPO-22-16362(R); Published: 04-Apr-2022, DOI: 10.35248/2329-6607.22.11.274.

Copyright: © 2022 Kubot I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.